Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid
profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol,
triglyceride) in patients with metabolic syndrome.